These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34972765)

  • 1. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia.
    Alonso-Vega C; Urbina JA; Sanz S; Pinazo MJ; Pinto JJ; Gonzalez VR; Rojas G; Ortiz L; Garcia W; Lozano D; Soy D; Maldonado RA; Nagarkatti R; Debrabant A; Schijman A; Thomas MC; López MC; Michael K; Ribeiro I; Gascon J; Torrico F; Almeida IC
    BMJ Open; 2021 Dec; 11(12):e052897. PubMed ID: 34972765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of pharmacological options for the treatment of Chagas disease.
    Lascano F; García Bournissen F; Altcheh J
    Br J Clin Pharmacol; 2022 Feb; 88(2):383-402. PubMed ID: 33314266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis.
    Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Ribeiro I; Villar JC; Sosa-Estani S
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008529. PubMed ID: 32804966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
    Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct evidence gap on fixed versus adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta-analysis.
    Ciapponi A; Barreira F; Perelli L; Bardach A; Gascón J; Molina I; Morillo C; Prado N; Riarte A; Torrico F; Villar JC; Reidel S; Gibbons L; Sosa-Estani S
    Trop Med Int Health; 2023 Jan; 28(1):2-16. PubMed ID: 36420767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ergosterol biosynthesis and drug development for Chagas disease.
    Urbina JA
    Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
    Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol.
    Cafferata ML; Toscani MA; Althabe F; Belizán JM; Bergel E; Berrueta M; Capparelli EV; Ciganda Á; Danesi E; Dumonteil E; Gibbons L; Gulayin PE; Herrera C; Momper JD; Rossi S; Shaffer JG; Schijman AG; Sosa-Estani S; Stella CB; Klein K; Buekens P
    Reprod Health; 2020 Aug; 17(1):128. PubMed ID: 32831069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review.
    Scarim CB; Ribeiro AR; Rosa JAD; Chin CM
    Rev Soc Bras Med Trop; 2018; 51(2):133-140. PubMed ID: 29768544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil.
    Ferreira AM; Sabino EC; de Oliveira LC; Oliveira CD; Cardoso CS; Ribeiro AL; Haikal DS
    PLoS One; 2016; 11(11):e0165950. PubMed ID: 27855177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental and Clinical Treatment of Chagas Disease: A Review.
    Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
    Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).
    Castro JA; Diaz de Toranzo EG
    Biomed Environ Sci; 1988 Jun; 1(1):19-33. PubMed ID: 3151755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.
    Hasslocher-Moreno AM; Saraiva RM; Sangenis LHC; Xavier SS; de Sousa AS; Costa AR; de Holanda MT; Veloso HH; Mendes FSNS; Costa FAC; Boia MN; Brasil PEAA; Carneiro FM; da Silva GMS; Mediano MFF
    EClinicalMedicine; 2021 Jan; 31():100694. PubMed ID: 33554085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform.
    Pinazo MJ; Pinto J; Ortiz L; Sánchez J; García W; Saravia R; Cortez MR; Moriana S; Grau E; Lozano D; Gascon J; Torrico F
    PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005770. PubMed ID: 28820896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte Transformation Test (LTT) in Allergy to Benznidazole: A Promising Approach.
    Marques-Mejías MA; Cabañas R; Ramírez E; Domínguez-Ortega J; Fiandor A; Trigo E; Quirce S; Bellón T
    Front Pharmacol; 2019; 10():469. PubMed ID: 31164819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.